Corvus Pharmaceuticals (CRVS) Falls on Profit-Taking After 212% Jump
In an updated report, Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc. (CRVS)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | OrbiMed Advisors Samuel Isaly | 7,165,006 | $55,170,546 | 1.13% | |
| 2. | Adams Street Partners Jeffrey Diehl | 3,275,616 | $25,222,243 | 9.56% | |
| 3. | Point72 Asset Management Steve Cohen | 2,875,000 | $22,137,500 | -56% | 0.02% |
| 4. | BioImpact Capital Mpm Capital | 2,743,671 | $21,126,267 | 2.42% | |
| 5. | Vivo Capital Albert Cha And Frank Kung | 2,234,566 | $17,206,158 | 1.11% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.73 | 20,000 | $34,624.00 | 153,773 | 2024-05-06 | Filing | |
| $1.73 | 577,634 | $999,999.98 | 577,634 | 2024-05-06 | Filing | |
| $2.45 | 10,000 | $24,500.00 | 10,000 | 2023-05-15 | Filing | |
| $0.79 | 20,000 | $15,800.00 | 133,773 | 2022-12-20 | Filing | |
| $0.84 | 4,000 | $3,364.00 | 133,238 | 2022-12-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.16 | 1,176,332 | $4,891,894.26 | 7,165,006 | 2025-06-27 | Filing | |
| $4.16 | 1,176,332 | $4,891,894.26 | 7,165,006 | 2025-06-27 | Filing | |
| $4.96 | 2,000,000 | $9,928,800.00 | 81,077 | 2021-10-01 | Filing | |
| $5.04 | 3,000,000 | $15,131,100.00 | 2,081,077 | 2021-09-30 | Filing | |
| $6.09 | 1,109,644 | $6,757,731.96 | 6,943,654 | 2021-09-20 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,056,361 | $38,933,979 | 0% | |
| 2. | 3,873,482 | $29,825,811 | 0% | |
| 3. | 3,567,908 | $27,472,892 | 0% | |
| 4. | 2,788,223 | $21,469,317 | 0% | |
| 5. | 1,473,026 | $11,345,051 | 0% |
News See All
Corvus Pharmaceuticals (CRVS) Soars 212% on Impressive Eczema Therapy Study
Corvus Pharmaceuticals soared by 211.8 percent week-on-week to hit a new all-time high, as investors cheered the strong results of its clinical trial testing the efficacy of soquelitinib in patients with...
Corvus Pharmaceuticals (CRVS) Hits All-Time High on Eczema Trial Results
Corvus Pharmaceuticals extended its winning streak to a 6th straight session on Thursday to hit a new all-time high, as investors cheered strong results from the clinical trial testing the efficacy of...
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q3 2025 Earnings Call Transcript
Operator: Good afternoon, everyone. Thank you for standing by, and welcome to the Corvus Pharmaceuticals Third Quarter 2025 Business Update and Financial Results Conference Call.
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q2 2025 Earnings Call Transcript
Operator: Good afternoon, everyone. Thank you for standing by, and welcome to the Corvus Pharmaceuticals Second Quarter 2025 Business Update and Financial Results Conference Call.
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q1 2025 Earnings Call Transcript
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q1 2025 Earnings Call Transcript May 8, 2025Corvus Pharmaceuticals, Inc. reports earnings inline with expectations.
10 Low Risk High Reward Stocks Set to Triple by 2030
The market is getting tough these days with increasing interest rates, tense world politics, and inconsistent economic conditions, and investors are constantly looking for opportunities.
10 Best Multibagger Penny Stocks to Buy According to Billionaires
Penny stocks always seem like bargains for gaining exposure to some of the fastest-growing segments or spectacles, especially when popular stocks cost hundreds or thousands of dollars.
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2024 Earnings Call Transcript
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2024 Earnings Call Transcript March 25, 2025Corvus Pharmaceuticals, Inc. misses on earnings expectations.
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q3 2024 Earnings Call Transcript
Operator: Good afternoon, everyone, and thank you for standing by, and welcome to the Corvus Pharmaceuticals Third Quarter 2024 Business Update and Financial Results Conference Call.
Hedge Fund Resource Center Billionaire Hedge Funds
